Which patients with NNRTI resistance mutations who wish to simplify their HIV antiretroviral regimens do you consider switching to cabotegravir/rilpivirine?

Personally, I would be cautious of using cab/rilpivirine in any patient with virologic failure and NNRTI resistance. However, the K103N mutation (signature resistance mutation in patients treated with efavirenz and nevirapine) is not associated with resistance to rilpivirine; these patients were inc...